8-K filing — Coya Therapeutics, Inc. (COYA)
Filed: 2026-10-14 AccNo: 0001193125-26-421066 Size: 148 KB Item 8.01: Other Events
Stocks · News reference
Coya Therapeutics Announces Publication Of Preclinical Results For COYA 303 In International Journal Of Molecular Sciences; Results Show Complementary Immunomodulatory Effects In Peripheral And CNS Inflammation
Study results showed complementary immunomodulatory effects of COYA 303, a combination of proprietary low-dose IL-2 (LD-IL2) and a GLP-1 Receptor Agonist (GLP-1RA), compared to either LD-IL2 or GLP-1RA as
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Coya Therapeutics Plans To Initiate Open-Label Extension Of Phase 2/3 ALSTARS Trial Evaluating COYA 302 For Treatment Of Amyotrophic Lateral Sclerosis
OLE planned in response to requests from ALSTARS investigators and participantsEligible participants completing 48 weeks of treatment will have the opportunity to continue receiving COYA 302Cash runway guidance remains
Coya Therapeutics Announces Full Enrollment Of Planned 120 Participants In Phase 2/3 ALSTARS Trial Evaluating COYA 302 For Potential Treatment Of Amyotrophic Lateral Sclerosis
120th participant has been enrolled in ALSTARS trial achieving target enrollmentAdditional eligible participants already in active screening will be allowed to enrollTopline data from 24-week double-blind treatment
BTIG Reiterates Buy on Coya Therapeutics, Maintains $16 Price Target
BTIG analyst Thomas Shrader reiterates Coya Therapeutics (NASDAQ:COYA) with a Buy and maintains $16 price target.